A5023189927- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Urologic and reproductive health conditions
- Peptidase Inhibition and Analysis
- Urological Disorders and Treatments
- Cancer Diagnosis and Treatment
- Testicular diseases and treatments
- Cancer Genomics and Diagnostics
- Health and Wellbeing Research
- Radiomics and Machine Learning in Medical Imaging
- Hormonal and reproductive studies
- Renal and related cancers
- Artificial Intelligence in Healthcare and Education
- Cancer survivorship and care
- Esophageal Cancer Research and Treatment
- Advanced Breast Cancer Therapies
- Advances in Oncology and Radiotherapy
- Health Systems, Economic Evaluations, Quality of Life
- Polyomavirus and related diseases
- Cancer, Lipids, and Metabolism
Ludwig-Maximilians-Universität München
2023-2025
LMU Klinikum
2023-2025
München Klinik
2024
PURPOSE The anti-NECTIN4 antibody-drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit only achieved in a small, yet uncharacterized patient subset. NECTIN4 located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) cancer. Here, we aimed to evaluate amplifications as genomic biomarker predict EV response mUC. MATERIALS AND METHODS We established NECTIN4-specific fluorescence...
Abstract Purpose Despite the high incidence of perioperative complications following cystectomy, there is a lack evidence regarding patients’ perceptions. Moreover, discrepancies between established complication grading systems and patient’s perspective remain unexplored. Methods We prospectively evaluated after cystectomy using Clavien-Dindo Classification (CDC) Comprehensive Complication Index (CCI). The CDC CCI were compared to patient-reported grades through Spearman correlation...
689 Background: Sarcopenia and skeletal muscle loss are associated with poor prognosis limited survival in metastatic cancer patients. This study aims to assess the impact of systemic treatment enfortumab vedotin pembrolizumab (EV/P) on index (L3SMI) patients urothelial carcinoma (mUC). Methods: We conducted a retrospective analysis mUC treated EV/P at single German tertiary care center. L3SMI was measured baseline (before treatment) first radiographic staging, approximately three months...
133 Background: There is an ongoing debate on the use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) following radical prostatectomy (RP). While there have been conflicting results regarding oncological outcome, effect concomitant ADT health-related quality life (HRQOL) remains elusive. We aimed to assess impact adding RT long-term HRQOL by providing PROM data from a large contemporary cohort patients undergoing RP systematic follow-up up 10 yrs....
766 Background: Bladder cancer (BC) patients from rural areas (RA) may have more difficult access to health care with potentially detrimental impact on oncological outcome following radical cystectomy (RC). However, little is known differences in health-related quality of life (HRQOL) between rural- and urban residents treated RC for BC. We therefore aimed assess these BC-patients by providing HRQOL data a large prospective cohort undergoing systematic follow-up up 10 yrs. Methods: n=1514...
496 Background: Papillary (pRCC) renal cell carcinoma is a rare cancer. We evaluated real-world treatment outcomes of 1st line in these cohorts Germany. Methods: Data were collected retrospectively from 13 GU cancer centres Patients (pts) with advanced or metastatic pRCC eligible. Adverse events (AEs) reported according to CTCAE 5.0. ORR was accessed local standard. Progression Free Survival (PFS) calculated start progression death. Descriptive statistics and KM-plots utilized, where...
Ziel/Aim: FAPI-PET may offer improved sensitivity in detecting metastatic urothelial carcinoma (UC). Emerging therapeutic strategies, such as the novel agent enfortumab vedotin combination with pembrolizumab (EV/P), exhibit enhanced anti-tumor activity first-line setting of advanced UC. This study aimed to compare treatment responses using FAPI-PET/CT imaging UC patients under EV/P therapy vs. traditional platinum-based chemotherapy (CTx).
436 Background: The standard first-line treatment for metastatic renal cancer (mRCC) combines immune checkpoint- (ICI) and tyrosine kinase inhibitors (TKI). While TKI therapy continues until disease progression, ICI is typically stopped after 24 months or 35 cycles, aligning with approval study criteria. However, in real-world practice, the decision to discontinue upon achieving a positive response can be distressing both patients healthcare providers; thus ICIs are not stopped. We conducted...
553 Background: Enfortumab vedotin (EV) is an antibody drug conjugate targeting Nectin-4. It was approved by EMA/FDA in patients (pts) with metastatic/ locally advanced urothelial cancer post platinum and immune check point inhibitors following the results of EV-301 trial. We report updated efficacy safety data EV a large European cohort real-world pts (GUARDIANS consortium) treated hospitals private practices. Methods: Retrospective were collected from 25 German Swiss practices for who...
Background: Our study endeavors to elucidate the clinical implications of PD-L1 positivity in individuals afflicted with advanced urothelial carcinoma bladder (UCB). Methods: Patients UCB were prospectively enrolled following a radical cystectomy (RC) performed within January 2017 December 2022 at our tertiary referral center. The outcome, defined as progression-free survival (PFS) and overall (OS) on systemic treatment, was analyzed using an χ2-test, Mann–Whitney U-test, Kaplan–Meier...
Immune checkpoint inhibitor (ICI) therapies have been established as the standard-of-care in various uro-oncological cancers. Immune-related adverse events (irAEs) are frequent, but their degree rarely leads to discontinuation of immunotherapies. Unplanned permanent treatment may negatively impact outcomes patients, there emerging data about a positive correlation between emergence severe irAEs and therapeutic cancer responses. In this study, retrospective analysis patients treated for...
e16616 Background: Artificial intelligence tools (AI) are increasingly used in all scientific fields. UTUC is rare form of kidney cancer and prognostic factors seem unclear. We sought to understand if AI could help identify parameters for overall survival aid the development a score. Methods: n=231 consecutive patients who underwent surgery between 2005 2020 were included. De-personalized data included age, gender, ECOG performance status, smoking habits, baseline creatinine platelets,...
Abstract Objectives While the impact of treatment with 5-alpha Reductase Inhibitors (5-ARI) on risk cancer-related mortality in men prostate cancer (PC) has been extensively studied, little is known about preoperative 5-ARI use patient-reported outcomes (PROs) following radical prostatectomy (RP). Methods Within our prospectively maintained institutional database 5899 patients treated RP for PC (2008– 2021), 99 therapy were identified. A 1:4 propensity-score matched analysis 442 ( n = 90...
185 Background: Several phase III trials have assessed efficacy and safety of 6 cycles docetaxel combined to androgen deprivation therapy (ADT). This is the current standard care for a subgroup patients. We aimed assess whether treatment beyond prove be more effective than care. Methods: retrospectively analyzed patients with histologically confirmed adenocarcinoma prostate radiologically proven metastatic disease from large tertiary center. All mHSPC were treated in first line ADT...
You have accessJournal of UrologyCME1 Apr 2023MP29-17 EFFICACY AND FEASIBILITY OF ADDITIONAL CYCLES DOCETAXEL IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY METASTATIC HORMONE-SENSITIVE PROSTATE CANCER Can Aydogdu, Florian Urban, Alexander Tamalunas, Elena Berg, Melanie Götz, Severin Rodler, Volker Heinemann, Christian G. Stief, and Jozefina Casuscelli AydogduCan Aydogdu More articles by this author , UrbanFlorian Urban TamalunasAlexander Tamalunas BergElena Berg GötzMelanie Götz...
e17074 Background: Several phase III trials have assessed efficacy and safety of 6 cycles docetaxel combined to androgen deprivation therapy (D-ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). This is the current standard care for a subgroup patients. We aimed assess whether treatment beyond prove be more effective than care. Methods: retrospectively collected data from patients with histologically confirmed adenocarcinoma radiologically proven disease treated at large tertiary...